Navigation Links
Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
Date:5/25/2010

LONDON, May 26 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the issuance of United States patent 7,723,316, titled Compositions and Methods of RNAi Therapeutics For Treatment of Cancer and Other Neovascularization Disease, by the United States Patent and Trademark Office (USPTO).  The issued patent, which deepens the Company's diverse portfolio of RNA interference (RNAi) intellectual property, is broadly directed to a double-stranded short interfering RNA (siRNA) sequence that targets vascular endothelial growth factor receptor 2 (VEGFR2).  VEGFR2 has been demonstrated to play an important role in the vasculogenic and angiogenic activities that contribute to the development and progression of tumors associated with a broad range of cancers.  The issued subject matter is not limited to the VEGFR2 compositions and also includes methods for reducing tumor growth.

"Silence is compiling a powerful portfolio of intellectual property with value tied to the unique scope of its issued claims and not simply a large number of owned patents.  Today's patent issuance fits perfectly with this strategy, as in our opinion, there are few disease targets with IP value comparable to VEGFR2," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "With its demonstrated connection to a broad host of cancers, among other disease areas, VEGFR2 is a target that we expect to help drive the expansion of Silence's RNAi therapeutics pipeline.  We view today's milestone as more than just another patent issuance; it is a development that significantly enhances the fundamental usefulness and functionality of our growing RNAi IP estate."

The specific composition of matter and method cl
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
2. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
3. Silence Therapeutics Announces Successful Opposition of Glover Patent
4. Organizational Changes at Silence Therapeutics
5. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
6. Silence Therapeutics Patent Update
7. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
8. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
9. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
10. Silence Therapeutics Appoints New Vice President of Research
11. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - SQI ... company that develops and commercializes proprietary technologies and products ... appointment of Peter Winkley to Chairman of ... Ricks .  Mr. Ricks will continue to serve as ... provide leadership to the Company.  "We ...
(Date:9/29/2014)... CIRENCESTER, England , September 29, 2014 /PRNewswire/ ... tighter margins and greater competition to transform network ... brand   ProLabs , ... infrastructure products, announced today the findings of their ... Optical Communications (ECOC) with top optical communications professionals ...
(Date:9/29/2014)... ZIONA, Israel , September 29, ... stage company developing novel immunomodulators for severe infections, today ... ( BARDA ) has awarded Atox Bio with a ... for the development of AB103 to treat Necrotizing Soft ... and public health threats that end in sepsis. ...
(Date:9/29/2014)... , Sept. 29, 2014 CytRx ... research and development company specializing in oncology, today ... (FDA) has granted multiple Orphan Drug Designations for ... indications: glioblastoma multiforme (GBM), small cell lung cancer ... of the widely-used chemotherapeutic agent, doxorubicin. ...
Breaking Biology Technology:SQI Diagnostics Announces New Chairman of Board of Directors 2End of an Era: OEM Dominance - Could it be a Thing of the Past? 2Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority (BARDA) 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 2CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 3CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 4CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer 5
... , LANSING, Mich., June 18 Fortune Magazine has ... in its annual list of the "40 best stocks to retire ... 40 list in 2002, stating: "We wanted to assemble a diversified, ... that could soar when the market did but also hold steady ...
... June 18 Environmental Tectonics Corporation,s (OTC Bulletin Board: ... the sale of an additional BARA-MED(R)XD monoplace hyperbaric oxygen ... The state-of-the-art monoplace chamber is among the first ... Oklahoma. , , Hyperbaric chambers are used ...
... FRANCISCO, June 18 Burrill & Company, a San ... Venture Capital, Private Equity, Merchant Banking and Media, is ... firm as Managing Director, Merchant Banking. Shawn will assist ... and capital raising transactions. In addition, Shawn will make ...
Cached Biology Technology:Neogen Named to Fortune's List of 40 Stocks 'To Retire On' 2Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 2Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 3Environmental Tectonics Corporation Announces Additional Hyperbaric Monoplace Chamber Sale to St. John Wound Center 4Shawn Cross Joins Burrill Merchant Banking 2Shawn Cross Joins Burrill Merchant Banking 3
(Date:9/29/2014)... A species of gut bacteria called Clostridium ramosum , ... weight. The work is published this week in mBio ... Microbiology. , A research team from the German Institute ... human gut bacteria including C. ramosum gained weight ... C. ramosum were less obese even when consuming ...
(Date:9/29/2014)... September 29: Between 1970 and 2010 populations of ... globe dropped 52 percent, says the 2014 Living ... (WWF). This biodiversity loss occurs disproportionately in low-income ... high-income countries. , In addition to the precipitous ... to other warning signs about the overall health ...
(Date:9/29/2014)... with children at home should use ventilation when cooking ... are recommending, after a new study showed an association ... and chronic bronchitis. , "In homes where a gas ... and wheezing is higher than in homes where a ... an associate professor in the College of Public Health ...
Breaking Biology News(10 mins):Gut bacteria promote obesity in mice 2Half of global wildlife lost, says new WWF report 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 2Childhood asthma linked to lack of ventilation for gas stoves, OSU study shows 3
... University of Alberta have pinpointed a genetic marker for sporadic ... in Caucasians., Researchers have identified many genetic markers for familial ... for 80 per cent of all cases. Sambasivarao Damaraju, a ... researcher at the Cross Cancer Institute, worked with his team ...
... a novel method of analyzing genetic variations in families, ... genetic variations affecting related biochemical processes may team up ... findings, reported May 28 in Translational Psychiatry , ... and schizophrenia, and may lead to a genetic test ...
... Osteoporosis Foundation,s key regional meeting in Hong Kong ... enriching scientific programme of direct relevance to your ... experts from around the world. http://www.iofbonehealth.org/hongkong-2013/ ... Plenary sessions devoted to epidemiology, ...
Cached Biology News:U of A medical researchers ID genetic marker for sporadic breast cancer 2Family studies suggest rare genetic mutations team up to cause schizophrenia 2
... Disposable. Virgin, optically clear polystyrene ... and alphanumeric coordinates for cell counting. ... number is a new product number, ... number. If showing no availability yet, ...
... The Luminex 100 IS System is a compact ... that integrates lasers, optics, fluidics, a controller, advanced ... This powerful, compact lab analysis system includes the ... Also, it has a DMF file at the ...
... gradient system is ideal for routine binary separations. ... sensitive Adept CE 4201 UV-Visible variable wavelength detector. ... provided by the two highly accurate and ... 4100 solvent delivery pumps., Chromatograms may be plotted ...
... Hep G2 cells were cultured in Minimum Essential ... at the log phase of growth. In ... forms, cells were fixed in acetone-methanol. The ... adhesive coated slide, with each wells surface specifically ...
Biology Products: